A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer

Ahmed Abdelgawad, Abdelwahab Hashem, Ahmed Mosbah, Laila A. Eissa

1 Biochemistry Department, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt, 2 Urology Department, Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

These authors contributed equally to this work.

*ahmedabdelgawad551@gmail.com

Abstract

Purpose

Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OHD) in suspected BC patients presented by hematuria.

Methods

This prospective cohort study involved suspected patients of BC presented with hematuria. Patients were evaluated by CT urogram, office cystoscopy and urine cytology with subsequent inpatient biopsy for positive findings. Baseline blood samples were collected for measurement of 25(OHD) by electrochemiluminescence binding assay at the time of diagnosis. Patients with non-muscle-invasive BC (NMIBC) underwent transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or BCG instillation. Patients were followed up for their recurrence status during 10 to 24 months. Recurrence was defined as the first time of NMIBC pathological relapse during the follow up period.

Results

A total of 115 patients were included in the final analysis. Patients had proven pathological BC (64 with NMIBC, and 20 with muscle invasive) and 31 patients were considered as control group. Controls were those patients with BC-free workup (including cytology, cystoscopy, and upper tract imaging). BC group showed a lower level of 25(OHD) than control group 16.47±5.88 versus 28.99±3.19 ng/mL (p<0.001). In addition, muscle invasive group also showed a lower level than NMIBC group 13.17±4.5 versus 17.49±5.04 ng/mL (P = 0.003). During the follow-up period of, tumor recurrence occurred in 16 (25%) of NMIBC patients. The baseline 25(OHD) were decreased in patients who experienced early recurrence; without being statistically significant (15.99 ± 5.17 vs. 18.38 ± 5.14 ng/mL; p = 0.08). 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC
Conclusion

Serum 25(OHD) is significantly decreased in BC patients especially those with tumor muscle invasive group. However, the baseline serum 25(OHD) does not predict the recurrence in the NMIBC patients.

Patients and methods

This is a single center prospective cohort study, had been conducted at Mansoura Urology and Nephrology Center, Egypt. Between August 2018 and May 2019, 140 Patients with hematuria were assessed for eligibility. Inclusion criteria included suspected patients of BC with gross or microscopic hematuria. Exclusion criteria were hematuria of other causes as trauma, stones, and infection, medical and nephrologic causes of hematuria, and patient having previous or current malignancy.

Preoperative evaluations included detailed medical history, physical examination, routine blood examination, urinalysis, renal and liver function tests, computed tomography with contrast scans. Outpatient office flexible cystoscopy and cytology were performed for patients...
with hematuria. BC-free patients by cystoscopy and cytology were considered as control patients.

Patients with positive/suspicious bladder lesion were inpatients admitted and underwent standard rigid cystoscopy and transurethral resection of bladder lesions were done to confirm or exclude malignancy. Immediate postoperative instillation of chemotherapy was done using Epirubicin 50 mg (2mg/ml) within the first 24hours.

Histo-pathology assessment was revised by a single expert uro-pathologist following the American pathologist protocol version 2012 [10]. cytology was evaluated according to the Paris classification system [11]. Suspicious and malignant samples were considered positive results, while, hyperplastic and negative for malignancy samples were considered negative results. Patients were followed according to the European guidelines 2015.v.1 for receiving intravesical instillation therapy [12].

All procedures in this study involving human participants were in accordance with the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all individual participants in this study after approval of the Institutional Review Board of faculty of Pharmacy ethical committee, Mansoura University (ID. R/2017-15).

Sample preparation and serum 25 (OHD) measurement

Vitamin D was determined by electrochemiluminescence binding assay on Elecsys and cobas e 601 immunoassay analyzers (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim).

The inter-series CV was of ≤ 20% and the sensitivity of the method was of (3–100) ng/ml. Vitamin D deficiency, insufficiency and sufficiency are defined as plasma 25 (OHD) concentration <12, 12–20, and >20 ng/mL, respectively, according to The Institute of Medicine guidelines [13].

Outcome measures. The primary endpoint was serum 25(OHD) levels and its diagnostic role in the staging and grading of BC patients through calculating the sensitivity, specificity, positive predictive value, and negative predictive value of serum 25(OHD). BC diagnosis was defined as discrimination of BC from BC-free (controls). BC stage was defined by differentiation of NMIBC from MIBC. BC grade was defined as discrimination of NMIBC grade into low and high grade according to WHO/ISUP 2004 grading system.

The secondary endpoint was the prognostic role of baseline serum 25(OHD) levels in the prediction of recurrence in patients with NMIBC at short-term follow-up. Recurrence was defined as the first time of tumor relapse regardless of tumor stage and grade.

Statistical analysis

Statistical analysis was performed with the use of the IBM SPSS Statistics version 22.0 for Windows (IBM Corp., Armonk, NY, USA). Statistical analyses were performed using chi-squared tests, Student’s t-test, Mann–Whitney-U test, as appropriate. A p-value <0.05 considered to be statistically significant.

Receiver operating characteristic (ROC) analyses were performed to determine the best sensitivity, specificity, diagnostic accuracy, and the area under the curve (AUC) with its 95% confidence interval (95% CI) for differentiating between the different subgroups. Kaplan–Meier analysis was utilized to determine the recurrence-free proportion, with significance determined by log-rank test. Univariable and multivariable Cox regression analyses were used to evaluate the factors affecting recurrence free rate.
Results

From August 2018 and May 2019, 140 patients met the eligibility criteria. After exclusion of patients with insufficient urine volume, invalid results, or error in processing of the samples, 115 patients were included in the analysis. Control patients were patients with a normal flexible cystoscopy, imaging, and cancer free cytology such as benign prostatic hyperplasia, chronic non-specific cystitis, polypoid cystitis, Bilharzial cystitis, and/or overactive bladder.

In this trial, 31 (27%) of included patients were bladder tumor free (controls) and the remaining 84 (73%) of patients had a pathological proven BC; 64 (55.7%) with NMIBC, and 20 (17.4%) with MIBC. Baseline patients and tumor characteristics demographics are shown in Table 1.

Serum 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC patients, respectively, (odds-ratios (OR): 2.13; 95% confidence intervals (CI), 1.52–2.99; P < 0.0001). Serum 25(OHD) deficiency/insufficiency occurred in 48(75%) and 16(80%) in non-muscle and muscle invasive BC patients, respectively, (OR: 1.25; 95% CI, 0.47–3.31; P = 0.65). Serum 25(OHD) deficiency/insufficiency occurred in 11(52.4%) and 37(86%) in low- and high-grade NMIBC patients, respectively, (OR: 2.06; 95% CI, 1.07–3.94; P = 0.003).

By assessing the role of 25(OHD) in BC diagnosis, BC group had a lower level of 25(OHD) than control group 16.47±5.88 versus 28.99±3.19 ng/mL (p<0.001) (S1A Fig). Based on ROC analysis (Fig 1A), a cut-off value of 24.17 ng/mL discriminates BC patients from controls with sensitivity and specificity of 0.99 and 0.81, respectively (Table 2).

MIBC patients showed a lower level than NMIBC patients’ group 13.17±4.5 versus 17.49±5.04 ng/mL, respectively (p<0.001) (S1B Fig). Based on ROC analysis (Fig 1B), a cut-off value of 13.45 ng/mL discriminates NMIBC from MIBC with sensitivity and specificity of 0.95 and 0.75, respectively (Table 2).

Regarding the serum 25(OHD) assumed task in discriminating NMIBC according to WHO/ISUP 2004 grading system into low and high grade, serum 25(OHD) showed a sensitivity (77%) and specificity (81%) for discrimination between low and high grade at a cut-off point 17.85 ng/ml (Fig 1C). However, serum 25(OHD) showed no significant difference between low and high grades patients (P = 0.25) (S1C Fig).

The median (interquartile range) of follow up period was 14 (11, 18) months for the NMIBC to detect the recurrence occurrence. Tumor recurrence occurred in 16 (25%) of those patients. Moreover, 25(OHD) showed no significant difference between recurrent and non-recurrent patients (P = 0.08) (S1D Fig). In addition, serum 25(OHD) did not predict the recurrence in NMIBC patients (Fig 1D).

Gender (P = 0.015) and tumor grade (WHO 1973 grading system) (P = 0.006) were the significant factor affecting tumor recurrence on univariate analysis (Table 3). Kaplan-Meier analysis that determine the recurrence-free proportion are shown in Figs 2 and 3. Using multivariable cox-regression analyses, gender did not significantly affect recurrence free survival [Hazard ratio (HR) (95% CI) = 0.69 (0.36–1.33) P = 0.27] and tumor grade was the only predictor for recurrence free survival [Hazard ratio (HR) (95% CI) = 0.44 (0.24–0.8) p = 0.008].

Discussion

In a pooled analysis of randomized trial and prospective cohort study, based on the inverse association between 25(OHD) and cancer risk, found that serum 25(OHD) concentrations ≥40 ng/ml was associated with > 65% reduction in risk of invasive cancers [14]. Sufficient vitamin D3 levels might play a role in the prevention or progression of BC. Zhao et al., [15] stated that serum 25(OHD) concentration is inversely correlated with BC risk.
Table 1. Baseline patients and tumors characteristics.

| Patients' baseline and tumor characteristics (N = 115) |
|------------------------------------------------------|
| Age, years, mean (SD) | 62 (10) |
| Gender ratio, male/female | 90 / 25 |
| Body mass index, Kg/m2, mean (SD) | 25.25 (5.5) |
| Serum 25-hydroxyvitamin D (25-OHD), ng/dl, mean (SD) | 19.62 (7.23) |
| Serum 25-hydroxyvitamin D (25-OHD), n (%) |
| Deficiency, <12 ng/mL | 28 (20) |
| Insufficiency, 12–20 ng/mL | 48 (34.3) |
| Sufficiency, >20 ng/mL | 64 (45.7) |
| Hematuria type, n (%) |
| Macroscopic | 97 (84.3) |
| Microscopic | 18 (15.7) |
| Asymptomatic | 12 (10.4) |
| Symptomatic | 6 (5.3) |
| Smoking history, n (%) |
| Never | 19 (16.5) |
| Former | 58 (50.4) |
| Current | 38 (33) |
| Cystoscopy findings, n (%) |
| Free | 31 (26.9) |
| Bladder mass | 84 (73) |
| Bladder cancer, n (%) |
| Non-muscle invasive | 64 (76.2) |
| Muscle invasive | 20 (23.8) |

Non-muscle invasive bladder tumor patients’ baseline and tumor characteristics (N = 64)

| Gender, n (%) |
|---------------|
| Male | 50 (78.1) |
| Female | 14 (21.9) |
| Age, n (%) |
| < 60 years | 28 (43.8) |
| 60–70 years | 33 (51.6) |
| > 70 years | 3 (4.7) |
| Body mass index, Kg/m2, n (%) |
| < 30 | 55 (85.9) |
| ≥ 30 | 9 (14.1) |
| Tumor number, n (%) |
| Single | 22 (34.4) |
| Multiple | 42 (65.6) |
| Tumor site, n (%) |
| Posterior | 13 (20.3) |
| Anterior | 6 (9.4) |
| Lateral | 8 (12.5) |
| Domal | 5 (7.8) |
| Multiple sites | 32 (50) |
| Tumor size, n (%) |
| < 3 cm | 16 (25) |
| ≥ 3 cm | 48 (75) |
| Tumor stage, n (%) | (Continued) |
Table 1. (Continued)

| Tumor grading system          | n (%)  |
|-------------------------------|--------|
| Associated CIS                | 0      |
| Tumor WHO 1973 grading system|        |
| G2                            | 31 (48.4) |
| G3                            | 33 (51.6) |
| Tumor WHO/ISUP 2004 grading system |    |
| Low grade                     | 21 (32.8) |
| High grade                    | 43 (67.2) |

https://doi.org/10.1371/journal.pone.0266371.t001

Fig 1. ROC curve for 25(OH)D in (A) bladder cancer patients vs. controls, (B) non-muscle invasive bladder cancer vs. Muscle invasive bladder cancer, (C) low-grade cancer vs. high-grade bladder cancer and (D) recurring bladder cancer vs non-recurrent bladder cancer.

https://doi.org/10.1371/journal.pone.0266371.g001
Vitamin D and its analogues are potential anti-proliferative agents, which decrease the high mitotic rate of BC, suppress tumor progression by stimulating apoptosis, reducing cell proliferation, and tumor invasion [15]. On the other hand, no statistically significant relationship has been found between serum vitamin D3 and BC in a Turkish study involving 101 BC patients and 109 controls [16].

In this present study, we observed significant lower serum levels of 25(OHD) in BC patients compared to BC-free (control) patients. Serum 25(OHD) deficiency/insufficiency occurred in 16.1% and 76.2% of control and BC patients, respectively. Serum 25(OHD) sufficiency was associated with lower risk for BC.

There is a paucity in the literature addressing serum 25(OHD) deficiency/insufficiency among NMIBC patients. NMIBC is highly immune-responsive disease with intravesical BCG 

### Table 2. Clinical performance characteristics of serum 25-hydroxyvitamin D in patients with hematuria for diagnosis, staging, grading of bladder cancer and prognosis of non-muscle invasive bladder cancer.

| Test | AUC | Cut off | 95% CI | Sensitivity | Specificity | PPV | NPV | Accuracy | P value |
|------|-----|---------|--------|------------|-------------|-----|-----|----------|---------|
| Bladder cancer versus control (bladder cancer-free) group | | | | | | | | | |
| 25-OHD | 0.991 | 24.17 | 98–100 | 0.99 | 0.81 | 0.93 | 0.96 | 0.93 | <0.001 |
| Non-muscle invasive bladder cancer versus Muscle invasive bladder cancer | | | | | | | | | |
| 25-OHD | 0.919 | 13.45 | 86–98 | 0.95 | 0.75 | 0.54 | 0.98 | 0.58 | <0.001 |
| High grade versus low grade non-muscle invasive bladder cancer | | | | | | | | | |
| 25-OHD | 0.816 | 17.85 | 70–93 | 0.77 | 0.81 | 0.89 | 0.63 | 0.78 | <0.001 |
| Recurrent versus non recurrent occurrence during short-term follow up non-muscle invasive bladder cancer | | | | | | | | | |
| 25-OHD | 0.487 | 15.3 | 32–66 | 0.81 | 0.83 | 0.62 | 0.93 | 0.83 | 0.917 |

AUC: area under the curve, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value.

Table 3. Analyses for predictors of recurrence among NMIBC patients.

| Variable | No recurrence (N = 48) | Recurrence (N = 16) | P-value |
|----------|------------------------|---------------------|---------|
| Age, n (%) | | | 0.94 |
| < 60 years | 21 (43.8) | 7 (43.8) | | |
| 60–70 years | 25 (52) | 8 (50) | | |
| > 70 years | 2 (4.2) | 1 (6.2) | | |
| Gender, n (%) | | | 0.015 |
| Male | 34 (70.8) | 16 (100) | | |
| Female | 14 (29.2) | 0 | | |
| Body mass index, Kg/m2, n (%) | | | 0.30 |
| < 30 | 40 (83.3) | 15 (93.8) | | |
| ≥ 30 | 8 (16.7) | 1 (6.2) | | |
| Tumor size, n (%) | | | 0.18 |
| < 3 cm | 14 (29.2) | 2 (12.5) | | |
| ≥ 3 cm | 34 (70.8) | 14 (87.5) | | |
| Tumor WHO 1973 grading system, n (%) | | | 0.006 |
| G2 | 28 (58.3) | 3 (18.8) | | |
| G3 | 20 (41.7) | 13 (81.3) | | |
| Tumor WHO/ISUP 2004 grading system, n (%) | | | 0.17 |
| Low grade | 18 (37.5) | 3 (18.8) | | |
| High grade | 30 (62.5) | 13 (81.3) | | |

https://doi.org/10.1371/journal.pone.0266371.t003
as the standard treatment for intermediate and high-risk disease to decrease recurrence and progression. Intravesical BCG induces a cell-mediated immunity, secretion of inflammatory cytokines and attraction of lymphocytes [8]. Vitamin D may play an immuno-regulatory role following BCG vaccination [17].

Fig 2. Kaplan-Meier survival curves showing recurrence-free survival of non-muscle invasive bladder cancer group in relation tumor grade (WHO/ISUP 2004 system).

https://doi.org/10.1371/journal.pone.0266371.g002

Fig 3. Kaplan-Meier survival curves showing recurrence-free survival of non-muscle invasive bladder cancer group in relation to gender.

https://doi.org/10.1371/journal.pone.0266371.g003
Amaral et al. [18] found that low plasma 25(OHD) concentrations were associated with an increased risk of BC, and this risk is higher among muscle invasive expressing low FGFR3 levels. Herein, we found that serum 25(OHD) deficiency/insufficiency occurred in 75% and 80% in non-muscle and muscle invasive bladder cancer patients, respectively. However, NMIBC patients also showed a significant higher level compared to MIBC patients’ group 17.49±5.04 and 13.17±4.5 ng/mL, respectively (p<0.001). Our findings need to be validated in a larger cohort.

Vitamin D could modulate cancer prognosis. A recent meta-analysis concluded that higher plasma 25(OHD) is associated with better overall survival for breast, haematological and colorectal cancers and better progression-free for breast, haematological and skin cancer [19]. Vitamin D could promote better cancer prognosis by inhibition of tumor growth, induction of differentiation, regulation of immune function, promotion of autophagy, and anti-inflammatory effects [20].

Ben Fradj et al. [21] followed 177 patients with NMIBC over 6 years. They found that recurrence, progression, and cancer-specific mortality risk were higher in patients with the lower plasma 25(OHD). In our trial, there was no significant relationship between serum levels of 25(OHD) and recurrence rate. These opposing results could be attributed to the short-term follow up period and a smaller sample size in our study. A larger cohort with a long-term follow up is needed.

This study has some limitations; serum 25(OHD) concentrations were assessed only once at the time of diagnosis and serum 25(OHD) concentrations could be changed over time during follow up, and thus could affect the outcomes. In addition, none of serum 25(OHD) deficiency/insufficiency patient had received vitamin D supplements or fortified food that could have influenced the recurrence rate. Also, we had only a short-term follow up that cannot precisely assess other prognostic values as progression and cancer-specific mortality.

Conclusion
Serum 25(OHD) is significantly decreased in bladder cancer patients, especially among those with muscle invasive tumor. However, baseline serum 25(OHD) does not predict recurrence in non-muscle invasive bladder cancer.

Supporting information
S1 Table. Reagents and working solutions used for measurements of 25(OH)D.
(DOCX)

S1 Fig. Serum 25-hydroxyvitamin D (mean SD) in our patients.
(DOCX)

Author Contributions
Formal analysis: Abdelwahab Hashem.
Methodology: Ahmed Abdelgawad.
Supervision: Ahmed Mosbah, Laila A. Eissa.
Writing – original draft: Ahmed Abdelgawad, Abdelwahab Hashem.
Writing – review & editing: Ahmed Mosbah, Laila A. Eissa.
References

1. Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of bladder cancer. Medical Sciences. 2020; 6(1):15. https://doi.org/10.3390/medsciences8010015 PMID: 32183076

2. Hashem A, Mosbah A, El-Tabey NA, Laymon M, Ibrahim E-H, Abd Elhamid M, et al. Holmium laser en-bloc resection versus conventional transurethral resection of bladder tumors for treatment of non-muscle-invasive bladder cancer: a randomized clinical trial. European Urology Focus. 2020. https://doi.org/10.1016/j.euf.2020.12.003 PMID: 33386289

3. Sanil O, Dobrush J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nature reviews Disease primers. 2017; 3(1):1–19.

4. Ritch CR, Velasquez MC, Kwon D, Becerra MF, Soodana-Prakash N, Attluri VS, et al. Use and validation of the AUA/SUO risk grouping for non-muscle invasive bladder cancer in a contemporary cohort. The Journal of urology. 2020; 203(3):505–11. https://doi.org/10.1097/JU.0000000000006593 PMID: 31609178

5. Van Den Bosch S, Witjes JA. Long-term cancer-specific survival in patients with high-risk, non–muscle-invasive bladder cancer and tumour progression: a systematic review. European urology. 2011; 60 (3):493–500. https://doi.org/10.1016/j.eururo.2011.05.045 PMID: 21664041

6. Pettencott C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nature reviews Urology. 2018; 15(10):615–25. https://doi.org/10.1038/s41585-018-0055-4 PMID: 29911725

7. Miyazaki J, Kawai K, Oikawa T, Johraku A, Hattori K, Shimazui T, et al. Uroepithelial cells can directly respond to Mycobacterium bovis bacillus Calmette-Guérin through Toll-like receptor signalling. BJU international. 2006; 97(4):860–4. https://doi.org/10.1111/j.1464-410X.2006.06026.x PMID: 16536788

8. Dunn JA, Jefferson K, MacDonald D, Iqbal G, Bland R. Low serum 25-hydroxyvitamin D is associated with increased bladder cancer risk: A systematic review and evidence of a potential mechanism. The Journal of steroid biochemistry and molecular biology. 2019; 188:134–40. https://doi.org/10.1016/j.jsbmb.2019.01.002 PMID: 30654104

9. Maalmi H, Ordoñez-Mena JM, Schöttker B, Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: systematic review and meta-analysis of prospective cohort studies. European journal of cancer. 2014; 50(8):1510–21. https://doi.org/10.1016/j.ejca.2014.02.006 PMID: 24582912

10. Mahul B. Amin, Brett Delahunt, Bernard H. Bochner, Jonathan I. Epstein, David J. Grignon, Peter A. Humphrey, et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Urinary Bladder October 2013 [updated October 2013. Available from: https://documents.cap.org/protocols/cp-urinary-bladder-2013-v3210.pdf.

11. Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DF, et al. The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. Acta cytoplogica. 2016; 60 (3):185–97. https://doi.org/10.1159/000446270 PMID: 27318895

12. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1 and CIS) 2015 [Available from: https://uroweb.org/wp-content/uploads/EAU-Guidelines-Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf.

13. Ross AC, Taylor CL, Yakline AL, Del Valle H. IOM (Institute of Medicine) Dietary reference intakes for calcium and vitamin D. Washington DC: The National Academies Press; 2011.

14. McDonnell SL, Baggeryll C, French CB, Bagggerly LL, Garland CF, Gorham ED, et al. Serum 25-hydroxyvitamin D concentrations > 40 ng/ml are associated with > 65% lower cancer risk: pooled analysis of randomized trial and prospective cohort study. PloS one. 2016; 11(4):e0152441. https://doi.org/10.1371/journal.pone.0152441 PMID: 27049526

15. Zhao Y, Chen C, Pan W, Gao M, He W, Mao R, et al. Comparative efficacy of vitamin D status in reducing the risk of bladder cancer: A systematic review and network meta-analysis. Nutrition. 2016; 32 (5):515–23. https://doi.org/10.1016/j.nut.2015.10.023 PMID: 26822497

16. Baykan O, Akgel M, Uren N, Yaman A, Tinay I, Ergul E, et al. The Relationship Between Urothelial Type Bladder Cancer, Plasma 25-Hydroxyvitamin D Levels, and Vitamin D Receptor Apal Bsmi Fokl, and TaqI Polymorphisms. Clinical laboratory. 2019; 65(4).

17. Lalor MK, Floyd S, Gorak-Stolinska P, Weir RE, Blitz R, Branson K, et al. BCG vaccination: a role for vitamin D? PLoS One. 2011; 6(1):e16709. https://doi.org/10.1371/journal.pone.0016709 PMID: 21304967

18. Amaral AF, Méndez-Pertuz M, Muñoz A, Silverman DT, Allory Y, Kogevinas M, et al. Plasma 25-Hydroxyvitamin D3 and Bladder Cancer Risk According to Tumor Stage and FGFR3 Status: A Mechanism-Based Epidemiological Study. JNCI: Journal of the National Cancer Institute. 2012; 104(24):1897–904. https://doi.org/10.1093/jnci/djs444 PMID: 23108201
19. Vaughan-Shaw P, O’sullivan F, Farrington S, Theodoratou E, Campbell H, Dunlop M, et al. The impact of vitamin D pathway genetic variation and circulating 25-hydroxyvitamin D on cancer outcome: systematic review and meta-analysis. British journal of cancer. 2017; 116(8):1092–110. https://doi.org/10.1038/bjc.2017.44 PMID: 28301870

20. Giammanco M, Di Majo D, La Guardia M, Aiello S, Crescimanno M, Flandina C, et al. Vitamin D in cancer chemoprevention. Pharmaceutical biology. 2015; 53(10):1399–434. https://doi.org/10.3109/13880209.2014.988274 PMID: 25856702

21. Ben Fadl MK, Bibi M, Hammami MB, Kallel A, Nouira Y, Feki M. Low plasma 25-hydroxyvitamin D at diagnosis predicts poor outcomes in patients with bladder cancer: a prospective cohort study. Nutrition and Cancer. 2021; 73(1):55–61. https://doi.org/10.1080/01635581.2020.1737150 PMID: 32672109